Abstract
Cardiovascular diseases remain the leading cause of global morbidity and mortality, imposing a significant burden on families and societies. E26 transformation‑specific (ETS)‑1 and ETS‑2, members of the ETS family of transcription factors (also known as proto‑oncogenes), are increasingly recognized for their roles in tumor progression. Recent studies highlight their importance in normal coronary artery development, myocardial homeostasis and the regulation of vascular inflammation and remodeling. Emerging evidence suggests that ETS‑1/ETS‑2 are critical in the pathogenesis of atherosclerosis, myocardial ischemia‑reperfusion injury, cardiac remodeling and heart failure. The present review summarized the research progress of ETS‑1/ETS‑2 in cardiovascular diseases, discusses the relevant challenges encountered in the translational process of ETS‑1/ETS‑2‑targeted therapy for cardiovascular diseases and provides novel strategies for the treatment of cardiovascular diseases targeting ETS‑1/ETS‑2.